Hamburger J I
J Clin Endocrinol Metab. 1985 May;60(5):1019-24. doi: 10.1210/jcem-60-5-1019.
Between 1961 and 1984, 262 patients with hyperthyroidism due to Graves' disease between the ages of 3 and 18 yr were treated in the author's clinic. This paper compares the results of different treatment methods. Initial treatment was surgery for 7 patients, radioiodine for 73, and an antithyroid drug for 182. Seven drug-treated patients subsequently had surgery. Of 14 surgically treated patients, 5 relapsed and received radioiodine, 5 became hypothyroid, 3 were lost to follow-up, and 1 remained euthyroid. Sixteen drug-treated patients were lost to follow-up; 7 are still taking drugs. Of the remaining 99 drug-treated patients not achieving remission, 92 received radioiodine, and 7 had surgery (1 later relapsed and received radioiodine). The principal reasons for abandoning drugs were toxicity, noncompliance, poor control, and failure to achieve sustained remissions. Of 61 drug-treated patients who achieved remission, 22 relapsed (21 were treated with radioiodine and 1 with drug). Remissions after antithyroid drug therapy persist in 39 patients, 2 of whom are now hypothyroid and 10 of whom have been in remission less than 2 yr. Of the 239 subjects whose treatment is complete, 191 (80%) ultimately had radioiodine. One radioiodine treatment eliminated hyperthyroidism in 163 patients, 2 treatments were effective in 17, and 3 treatments were effective in 1. The remaining 5 patients were lost to follow-up after radioiodine before the outcome of therapy could be determined. No increase in congenital abnormalities was found in 63 children of these patients, regardless of treatment. Radioiodine is a safe, simple, and economical therapy for patients with hyperthyroidism and is now considered the initial treatment of choice for such patients.
1961年至1984年间,作者所在诊所共治疗了262例年龄在3至18岁之间的格雷夫斯病所致甲状腺功能亢进患者。本文比较了不同治疗方法的结果。初始治疗时,7例患者接受手术治疗,73例接受放射性碘治疗,182例接受抗甲状腺药物治疗。7例接受药物治疗的患者随后接受了手术。在14例接受手术治疗的患者中,5例复发并接受了放射性碘治疗,5例出现甲状腺功能减退,3例失访,1例甲状腺功能维持正常。16例接受药物治疗的患者失访;7例仍在服药。在其余99例未缓解的接受药物治疗的患者中,92例接受了放射性碘治疗,7例接受了手术(1例后来复发并接受了放射性碘治疗)。放弃药物治疗的主要原因是毒性、不依从、控制不佳以及未能实现持续缓解。在61例实现缓解的接受药物治疗的患者中,22例复发(21例接受放射性碘治疗,1例接受药物治疗)。抗甲状腺药物治疗后缓解的患者有39例,其中2例现患甲状腺功能减退,10例缓解时间不足2年。在239例完成治疗的患者中,191例(80%)最终接受了放射性碘治疗。1次放射性碘治疗使163例患者的甲状腺功能亢进得以消除,2次治疗使17例有效,3次治疗使1例有效。其余5例患者在接受放射性碘治疗后失访,治疗结果尚未确定。这些患者的63名子女中,无论接受何种治疗,均未发现先天性异常增加。放射性碘对甲状腺功能亢进患者来说是一种安全、简单且经济的治疗方法,现在被认为是此类患者的首选初始治疗方法。